Asia-Pacific Hemophilia A and B Therapeutics Market Pipeline Landscape and Growth Assessment by 2023: Research Anticipates 8.6% CAGR
Hemophilia A and B are inherited bleeding disorders caused by the deficiency of blood clotting factor VIII (FVIII) or factor IX (FIX), respectively. It is affecting more than 400,000 people worldwide. Considering this fact, novel treatments for people suffering from hemophilia and other different bleeding problems has evolved over the past. With a prime focus on Asia-Pacific Market, a study titled "Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2023" has been broadcasted to the online repository of Market...
View full press release